RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on Biomarin Pharmaceutical but lowers the price target from $100 to $85.
September 17, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Biomarin Pharmaceutical but has lowered the price target from $100 to $85, indicating a less optimistic outlook.
The lowering of the price target from $100 to $85 by RBC Capital suggests a less optimistic view on Biomarin's future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100